Previous 10 | Next 10 |
Epizyme ( EPZM ) specializes in an epigenetic therapy approach to human diseases, including cancers. This is a new field and potentially a revolutionary one. Proving a drug from the epigenetics platform can work well enough to get FDA approval would be a big advance for medicine and biotechnol...
Introduction to the Positive/Negative Forensic Value Stock Selections This quantitative study continues a series of multi-year test of the top three forensic algorithms used to detect bankruptcy risk, earnings manipulation, and financial irregularities. My forward testing compiles portfolio ...
SPDR Biotech ETF (NYSE: XBI ) provides investors diversified exposure to one of the most exciting industries in the market. Diversified is a relative term here because biotechnology companies, particularly those that are still in early stages of drug development, are often times the riskie...
New Clinical Data Presented Today Included in Recently Submitted NDA to FDA Epizyme, Inc . (Nasdaq: EPZM), a late-stage biopharmaceutical company developing novel epigenetic therapies, today reported updated data on tazemetostat from the epithelioid sarcoma cohort of its ongoing Phas...
Epizyme (NASDAQ: EPZM ) has submitted a New Drug Application (NDA) to the FDA for accelerated approval of tazemetostat for the treatment of patients with metastatic or locally advanced epithelioid sarcoma not eligible for curative surgery. More news on: Epizyme, Inc., Healthcare sto...
Submission Follows Productive Pre-NDA Meeting and Marks On-time Execution of First of Two NDA Submissions Planned for 2019 Epizyme, Inc. (Nasdaq: EPZM), a late-stage biopharmaceutical company developing novel epigenetic therapies, today announced that it has submitted a New Drug App...
Epizyme, Inc. (Nasdaq: EPZM), a late-stage biopharmaceutical company developing novel epigenetic therapies, today announced that Robert Bazemore, president and chief executive officer, will present at the Jefferies 2019 Healthcare Conference on June 5, 2019 at 3:00 p.m. ET in New York City...
Epizyme, Inc. (Nasdaq: EPZM), a late-stage biopharmaceutical company developing novel epigenetic therapies, today announced that new data from the epithelioid sarcoma and follicular lymphoma cohorts of the company’s ongoing Phase 2 clinical trials of tazemetostat will be reported duri...
Epizyme ( EPZM ) Q1 results : Revenues: $7.9M. More news on: Epizyme, Inc., Healthcare stocks news, Earnings news and commentary, Read more ...
Epizyme (NASDAQ: EPZM ): Q1 GAAP EPS of -$0.39 beats by $0.05 . Revenue of $7.9M vs. consensus of $0.32M. Press Release More news on: Epizyme, Inc., Earnings news and commentary, Healthcare stocks news,
News, Short Squeeze, Breakout and More Instantly...
TAZVERIK® (tazemetostat) Net Product Revenue of $11.0 Million for 2Q 2022; Total End User Demand Grew 17% vs. 1Q 2022 First Patient Dosed in the SET-101 Phase 1/1b Study of EZM0414, the Company’s Novel, First-in-Class, Oral SETD2 Inhibitor Merger with I...
The biotech investment sector has always been its own market, very distinct from other sectors. So it was no surprise that when most sectors turned slowly upward after the pandemic-inspired crash, Biotech (XBI) rose 164%, exceeding the overall market (SPY) performance by triple digits. Then, a...
Shares of the commercial-stage cancer company Epizyme (NASDAQ: EPZM) are soaring today. Specifically, the drugmaker's stock is up by a handsome 58% as of 10:50 a.m. ET Monday. Epizyme's shares are racing higher today in response to a buyout agreement with French biopharma Ipse...